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Abstract
Introduction The aim of the present study was to identify the
relationships between the uptake of radiotracers – namely
pentavalent dimercaptosuccinic acid [(V)DMSA] and sestamibi
(MIBI) – and the following parameters in primary breast cancer:
steroid receptor concentrations (i.e. estrogen receptor [ER] and
progesterone receptor [PR]), Ki-67 expression, tumor size,
tumor grade, age, and levels of expression of p53 and c-erbB-2.
In addition, by multivariate regression analysis, we further
isolated those factors with independent associations with
(V)DMSA and/or MIBI uptake in primary breast cancer.
Methods Thirty-four patients with histologically confirmed
breast carcinoma underwent preoperative scintimammography
with technetium-99m (99mTc)-(V)DMSA and/or 99mTc-MIBI in
consecutive sessions 10 and 60 min after administration of
925–1110 MBq of each radiotracer. The tumor-to-background
ratio was calculated and correlated with the presence of ER,
PR, Ki-67, tumor size, tumor grade, p53, and c-erbB-2. ER, PR,
p53, and c-erbB-2 were determined immunohistochemically.
The analysis included tumor-to-background ratio of (V)DMSA
and MIBI uptake as dependent and all of the other parameters
as independent variables.
Results Correlation was positive between Ki-67 and (V)DMSA
(r=0.37 at 10 min, P=0.038; r=0.42 at 60 min, P=0.018)
and inverse between PR and (V)DMSA uptake (r=–0.46 at
10 min, P=0.010; r=–0.51 at 60 min, P=0.003). Multivariate
regression analysis demonstrated a positive correlation
between Ki-67 and (V)DMSA at 60 min (P=0.045). Ki-67 was
not significantly correlated with MIBI uptake, whereas tumor
size was positively correlated with MIBI uptake at 60 min both
in univariate (r=0.45,  P=0.027) and multivariate analysis
(P=0.024). Negative correlations were observed between
(V)DMSA uptake and ER, as well as between ER/PR and MIBI
uptake, but these were not significant.
Conclusion Ki-67 appears to represent the major independent
factor affecting (V)DMSA uptake in breast cancer. Tumor size
was the only independent parameter influencing MIBI uptake in
breast cancer. (V)DMSA appears to have an advantage over
MIBI in that it can be used to visualize tumors with intense
proliferative activity, and thus it can identify those tumors that
are more aggressive.
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Introduction
Several factors have been reported to be able to predict
the biological behavior and clinical outcome of breast
cancer, including proliferation index, tumor suppressor
gene p53, over-expression of oncoprotein c-erbB-2, tumor
size, age, steroid receptors, and grade of malignancy. Of
these, proliferation rate is the most important parameter in
predicting tumor aggressiveness and prognosis. Many
attempts have recently been made to define more accu-
rately a specific agent with which to image the proliferative
activity of breast lesions using [18F]-fluoro-2-deoxy-D-
glucose positron emission tomography, [18F]3′-deoxy-3′-
fluorothymidine positron emission tomography, and
deoxyuridine, with ambiguous results [1–3].
Pentavalent dimercaptosuccinic acid [(V)DMSA] and
hexakis-2-methoxyisobutylisonitrile (sestamibi [MIBI])
appear to have different mechanisms of accumulation in
tumor, which have not yet been completely clarified. Tech-
netium-99m (99mTc)-MIBI has been widely used for the past
5 years and has contributed significantly to the diagnosis of
breast cancer, especially in circumstances that hinder mam-
mographic diagnosis, such as dense breasts, scars, and
implants. 99mTc-MIBI is concentrated in cancer cells by an
energy requiring transport mechanism and transmembrane
electronegative potential, in addition to nonspecific mecha-
nisms, and it is stored within the mitochondria. 99mTc-
(V)DMSA is a tumor seeking agent [4,5] that is known for its
ability to detect medullary thyroid carcinoma [6], soft tissue
tumors [7,8], lung cancer [9], metastatic disease [10], and
brain tumors [11,12]. Its mechanism of accumulation has
been thought to be related to the structural similarity
between (V)DMSA core and PO4
–3, which is avidly taken up
by some cancer cells [13,14]. In a poorly differentiated
breast cancer model, Palmedo and coworkers [15] reported
that uptake of (V)DMSA was more than twofold greater than
that of MIBI. Horiuchi and colleagues [16] reported that
99mTc-(V)DMSA uptake by tumors was related to glucose
mediated acidosis.
We have conducted many comparative studies with
(V)DMSA and MIBI in an attempt to identify their charac-
teristics in detecting primary breast cancer and lymph
node involvement, in defining tumor grade, and in visualiz-
ing preinvasive lesions such as ductal carcinoma in situ
(DCIS)/lobular carcinoma in situ and epithelial hyperpla-
sia, as well as their relationship with prognostic factors
[17–21]. Apart from what was considered until now to be
its main mechanism of concentration in breast cancer,
(V)DMSA was found by simple [22] and multivariate
regression analysis [23] to be related to proliferative activ-
ity in invasive and preinvasive breast lesions, which is
directly related to tumor grade.
The aim of the present study was to determine the possi-
ble independent correlation between proliferative activity
and other important prognostic factors, and (V)DMSA and
MIBI uptake in breast cancer.
Materials and method
Patients
The series consisted of 34 patients (age 61.6±12.49 years
[mean±standard deviation], range 38–85 years) with his-
tologically proven breast cancer (infiltrating ductal 13, infil-
trating lobular 9, tubular 1, mixed ductal and lobular 3, and
infiltrating ductal plus in situ ductal 8). Twenty one of
these patients underwent both 99mTc-(V)DMSA and
99mTc-MIBI scintigraphy in a double phase study, with an
interval of 48 hours between the two tests. Ten patients
underwent only 99mTc-(V)DMSA scintigraphy and three
patients underwent only 99mTc-MIBI scintigraphy. Thus, a
total of 31 patients underwent 99mTc-(V)DMSA and 24
underwent  99mTc-MIBI scintigraphy. Lateral prone and
anterior supine images were acquired at approximately 15
and 60 min after administration of 925–1110 MBq of
each radiotracer. Acquisitions were obtained using a
special positioning pad (PBI-2 Scintimammography Pad
Set®; Pinestar Technology Inc., Greenville, PA, and Som-
erset, NJ, USA).
Inclusion criteria for entry into the study were as follows:
female sex, age greater than 21 years, not pregnant, suspi-
cious lesion of the breast detected by palpation or mam-
mography, recommendation for excisional biopsy after
mammography, and informed consent. Exclusion criteria
were recurrent disease, previous mastectomy, medically
unstable patient with severe arrhythmia, heart failure or
recent surgery, fine needle aspiration within 1 week before
scintimammography, core biopsy during the previous
4 weeks, and previous chemotherapy.
Scintimammography was performed using a single-head
γcamera (Sophycamera DS7; Sopha Medical Vision Inter-
national, Buc Cedex, France) equipped with a high-resolu-
tion parallel hole collimator connected to a dedicated
computer (Sophy NxT; Sopha Medical Vision Interna-
tional). The matrix was 256×256 pixels and the photo-
peak was focused at 140KeV with a symmetric 10%
window. Scintimammography findings were characterized
by two experienced nuclear medicine physicians as posi-
tive, suspicious, or negative. Disagreement was resolved
by consensus or by obtaining a third opinion. The pres-
ence of focal increased activity, as compared with sur-
rounding tissue, was classified as a positive study.
99mTc-(V)DMSA was prepared using a commercially avail-
able kit (DMS(V)/Demoscan®; distributed by the National
Center of Physical Sciences, Institute of Radioisotopes
and Radiodiagnostics ‘Democritos’, Athens, Greece), con-
taining 1.36mg dimercaptosuccinic acid, 0.105mg
SnCl2
–2H2O, 0.175mg ascorbic acid, 12.5mg inositole,
10mg dextrose, 16.52mg and 200µl 7% NaHCO3,Breast Cancer Research    Vol 6 No 2 Papantoniou et al.
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which was reconstituted with 2–3ml 99mTc-pertechnetate
solution (approximately 925–1110MBq). Sestamibi kit
(Cardiolite®), obtained from Bristol Myers Squibb GmbH
(Regensburg, Germany), was labeled with 99mTc within
the Department of Nuclear Medicine.
Diagnosis was made by histopathology of the specimens
obtained surgically. Scintigraphic results and mammo-
grams were compared with histologic findings.
Image analysis
Accumulation of radiopharmaceutical in breast tumors
was evaluated in early and delayed images visually and by
calculating tumor-to-background ratio using regions of
interest of standardized shape and size over the site of the
greatest activity and the surrounding normal breast tissue.
The same procedure was also performed with regions of
maximum and minimum activity in the contralateral normal
breast.
Immunostaining
An immunohistochemical method (avidin–biotin–peroxi-
dase complex; ABC-HRP) was performed on paraffin
embedded sections from breast cancer patients for
demonstration of estrogen receptor (ER), progesterone
receptor (PR), p53, c-erbB-2, and Ki-67 protein expres-
sion. For ER and PR receptor proteins the 1D5 and 1A6
monoclonal antibodies (DAKO, Glostrup, Denmark) were
used at dilutions of 1:400 and 1:150, respectively. For
p53 protein determination the specimens were incubated
with 1:15 diluted monoclonal antibody (Clone
BPS3.12.1; Oncogene Science, Cambridge, MA, USA).
CB11 monoclonal antibody (Biogenex, San Ramon, CA,
USA) was used for c-erbB-2 detection at a dilution of
1:150. A polyclonal antibody for Ki-67 (DAKO) was used
at a dilution of 1:350. To enhance antigen retrieval, sec-
tions for ER, PR, and Ki-67 were microwave treated in
0.01 M citrate buffer (pH 6.0) at 750W for 10 min.
A semiquantitative estimation based on the staining inten-
sity and the percentage of positive cells was performed.
Staining for ER and PR was evaluated using the H score
system, and a score greater than 50 was considered posi-
tive for both antigens (0=negative [0–50], 1=mild reac-
tivity [51–100], 2=moderate reactivity [101–200],
3=strong reactivity [201–300]). Staining for p53,
c-erbB-2, and Ki-67 was scored on a scale from 0 to 3 in
half steps (0=negative [0–10% positive cells],
1=11–30% positive cells, 2=31–50% positive cells,
3=>51% positive cells).
Data analysis
Patients were classified into four subgroups: groups 1 and
2 for early and late (V)DMSA acquisitions, respectively;
and groups 3 and 4 for early and late MIBI acquisitions,
respectively. To investigate which factors play important
roles in the uptake of these radiotracers, we used both uni-
variate and multivariate analysis. In univariate analysis we
used the method of Spearman rank correlation to test
whether there was a significant correlation between the
uptake ratio (tumor-to-background ratio) and the variables of
interest. Each analysis was performed within the four sub-
groups. In multivariate analysis, we used the method of step-
wise multivariate linear regression for each subgroup. For all
tests, P<0.05 was considered statistically significant.
Results
Tumor-to-background ratios for (V)DMSA and MIBI
ranged from 1.13 to 2.80 (1.69±0.49 [mean±standard
deviation]) and from 1.13 to 4.78 (1.96±0.92), respec-
tively. Descriptive statistics for all dependent parameters
are listed in Table 1. Information concerning tumor grade,
tumor size, and age of patients is presented in Table 2.
Proliferative index (Ki-67)
Linear regression univariate analysis revealed a significant
positive correlation between Ki-67 and (V)DMSA uptake
in early and late phases (r=0.37 at 10 min, P=0.038;
r=0.42 at 60 min, P=0.018; Fig.1). Simple regression
analysis could not identify any correlation of Ki-67 with
MIBI uptake.
Multivariate analysis demonstrated a positive correlation of
Ki-67 with (V)DMSA (P=0.045) but not with MIBI
(Table 3). If c-erbB-2 and p53 are excluded from the multi-
variate analysis, then the statistical significance of the cor-
relation becomes greater (P=0.023).
Estrogen and progesterone receptors
Using simple univariate analysis, inverse (negative) corre-
lations between PRs and (V)DMSA uptake were found at
10 and 60 min (r=–0.46 at 10 min, P=0.010; r=–0.51
at 60 min, P=0.003; Table 4, Figs 2 and 3). MIBI uptake
was inversely but not significantly correlated with ER/PR
receptors, despite its tendency to be related to lower
ER/PR values.
Multivariate analysis did not reveal any significant correla-
tion of uptake of either radiotracer with ER/PR receptor
status.
Tumor size
Tumor size was positively correlated in univariate and mul-
tivariate analyses with MIBI uptake at 60 min (r=0.45,
P=0.027 for univariate analysis; and P=0.024 for multi-
variate analysis; Tables 3 and 4, Fig.4). (V)DMSA was not
found to be correlated with tumor size.
Grade of malignancy, age, and expressions of p53 and
c-erbB-2
None of these parameters was significantly correlated with
tumor (V)DMSA or MIBI uptake.Discussion
The prognosis of breast cancer depends not only on the
extent of the disease but also on the biological behavior of
the tumor, which is based on physical, histologic, and
immunohistochemical characteristics. Steroid receptor
status, loss of differentiation, increasing proliferative activ-
ity, inactivation of tumor suppressor genes, over-expres-
sion of oncogenes, tumor size, and age are related to
tumor progression and may be used to predict prognosis.
Although the exact mechanism of tumor accumulation and
the kinetics of the tracers MIBI and (V)DMSA have not yet
been fully clarified, their possible correlation with some of
these parameters should be of great importance in preop-
erative evaluation and prognostication in this disease.
Available online http://breast-cancer-research.com/content/6/2/R56
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Table 1
Values for parameters studied in the tumors
Standard
Minimum Maximum Mean deviation
Age (years) 38 85 61.58 12.49
Tumor Size (cm) 1 6 2.82 1.34
Estrogen receptor 0 250 134 84.53
Progesterone receptor 0 240 75.52 69.85
p53 0 100 10.42 13.95
Ki-67 0 210 62.58 63.49
c-erbB-2 0 100 11.54 23.46
Table 2
Distribution of studied material according to grade and size of
tumor and patient age
Frequency Percentage
Grade
I 4 11.7%
II 20 58.8%
III 10 29.4%
Size
T1 5 14.7%
T2 27 79.4%
T3 2 5.8%
Age (years)
< 40 4 11.7%
41–50 6 17.6%
51–60 6 17.6%
61–70 12 35.2%
≥ 71 6 17.6%
Table 3
Significant regression coefficients with standard errors and P
values of the full model for 99mTc-(V)DMSA and 99mTc-MIBI
uptake
Standard error P
(V)DMSA at 60 min: Ki-67 0.002 0.045
MIBI at 60 min: tumor size 0.141 0.024
MIBI, sestamibi; 99mTc, technitium-99m; (V)DMSA, pentavalent
dimercaptosuccinic acid.
Figure 1
Correlation of Ki-67 with log transformed tumor-to-background ratios
(T/B) of pentavalent dimercaptosuccinic acid [(V)DMSA] uptake at 
(a) 10 min and (b) 60 min, and sestamibi (MIBI) uptake at (c) 10 min
and (d) 60 min. CI, confidence interval.
Figure 2
Correlation of estrogen receptor (ER) with log transformed tumor-to-
background ratios (T/B) of pentavalent dimercaptosuccinic acid
[(V)DMSA] uptake at (a) 10 min and (b) 60 min, and sestamibi (MIBI)
uptake at (c) 10 min and (d) 60 minutes. CI, confidence interval.Scintimammography with 99mTc-MIBI and 99mTc-(V)DMSA
is a useful technique that is complementary to mammogra-
phy in the assessment of suspected breast lesions. It has
been reported to have high sensitivity (88.4%), specificity
(93.3%), positive predictive value (95%), negative predic-
tive value [82% for MIBI, 80% for (V)DMSA], and accu-
racy [90% for MIBI, 89% for (V)DMSA] for lesions greater
than 1cm in size; however, these values are less for
lesions sized smaller than 1cm, which might be consid-
ered a limitation of the procedure [20,24,25].
Arrest of tumor cell proliferation is the ultimate objective of
anticancer therapy. Breast cancer aggressiveness
appears to be directly related to the percentage of Ki-67
positive cancer cells [26]. The immunohistochemical
expression of Ki-67 appears to be associated with the
grade of differentiation, angiogenic invasion, lymph node
metastases, and the absence of ER and PR [26]. In our
group of patients there was a positive correlation in uni-
variate analysis between 99mTc-(V)DMSA tumor uptake
and Ki-67 expression in both early and late phases, which
Breast Cancer Research    Vol 6 No 2 Papantoniou et al.
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Table 4
Correlation coefficients and their significance for the four groups
ER PR Ki-67 Tumor size Age p53 c-erbB-2
(V)DMSA 10 min
r –0.24 –0.46 0.37 0.32 0.30 –0.06 –0.09
P 0.187 0.010 0.038 0.081 0.093 0.745 0.640
(V)DMSA 60 min
r –0.26 –0.51 0.42 0.25 0.22 0.23 0.09
P 0.157 0.003 0.018 0.178 0.226 0.206 0.617
MIBI 10 min
r –0.02 –0.25 0.23 0.29 0.19 0.33 –0.11
P 0.917 0.250 0.279 0.166 0.372 0.121 0.626
MIBI 60 min
r –0.01 –0.27 0.35 0.45 0.27 0.22 –0.04
P 0.953 0.211 0.097 0.027 0.202 0.305 0.848
ER, estrogen receptor; MIBI, sestamibi; PR, progesterone receptor; (V)DMSA, pentavalent dimercaptosuccinic acid.
Figure 3
Correlation of progesterone receptor (PR) with log transformed tumor-
to-background ratios (T/B) of pentavalent dimercaptosuccinic acid
[(V)DMSA] uptake at (a) 10 min and (b) 60 min, and sestamibi (MIBI)
uptake at (c) 10 min and (d) 60 min. CI, confidence interval.
Figure 4
Correlation of tumor size (TS) with log transformed tumor-to-
background ratios (T/B) of pentavalent dimercaptosuccinic acid
[(V)DMSA] uptake at (a) 10 min and (b) 60 min, and sestamibi (MIBI)
uptake at (c) 10 min and (d) 60 min. CI, confidence interval.was more prominent in the late phase. This relationship
was found in multivariate regression analysis to be inde-
pendent of the presence of other prognostic factors,
which indicates the existence of a separate primary
pathway for the mechanism of accumulation of (V)DMSA
in tumor tissue. This is considered to reflect its uptake in
structures that participate in mitotic activity of cancerous
and precancerous cell populations. The inverse correlation
found between PR and (V)DMSA uptake strengthened our
previous finding, because Ki-67 positivity is inversely cor-
related with the presence of PR receptors.
99mTc-MIBI exhibited no correlation with Ki-67 in univariate
and multivariate analyses. This indicates that this parame-
ter could not represent an important regulating factor in
MIBI accumulation in tumor tissue.
Cwikla and coworkers [27], in a group of 79 patients with
breast cancer, also found a negative correlation of PR and
a borderline negative correlation of ER with MIBI uptake.
However, they did not find a significant correlation
between Ki-67 expression and MIBI uptake (P=0.09).
Cutrone and coworkers [28] reported a moderate positive
correlation between MIBI uptake and cellular proliferation
(P<0.05) in a group of 42 patients with breast cancer.
Ohira and coworkers [29] found that MIBI uptake did not
reflect tumor growth rate in three animal models of breast
cancer. However, it must be borne in mind that all of those
investigators used only simple univariate analysis.
For (V)DMSA, preliminary reports from our center
[20,30–32] indicate that preinvasive breast lesions such as
DCIS/lobular carcinoma in situ and epithelial hyperplasia,
and especially those with moderate to intense Ki-67
expression (unpublished data), can be identified with high
sensitivity by (V)DMSA scintimammography. Mitotic activity
and cellular proliferation are the hallmarks not only of inva-
sive cancers but also of in situ or premalignant lesions
such as atypical epithelial hyperplasia and tumors with
unpredictable biologic behaviour such as phyllodes tumors.
These lesions have been identified more frequently and
more intensely with (V)DMSA than with MIBI [20].
Tumor size was positively correlated with MIBI uptake at
60 min (r=0.45, P=0.027), but not with (V)DMSA uptake,
in univariate analysis. Multivariate analysis demonstrated
independent correlation only with MIBI uptake at 60 min
(P=0.024). This finding indicates that MIBI concentration
reflects more accurately the number of metabolically active
cancer cells but does not represent tumor growth or cell
proliferation. This independent correlation was found only
at 60 min and shows that tumor vascularity was not
involved in this process. The nondependency of (V)DMSA
uptake with tumor size could be explained as a result of the
heterogeneity of Ki-67 expression in different parts of the
tumor. Cwikla and coworkers [27] also found a positive
correlation between MIBI uptake and size of the tumor in a
group of 79 patients with breast cancer (P=0.01).
Tumor grading using Bloom–Richardson’s criteria could in
theory be considered another variable that is closely related
to proliferative activity and to tumor uptake of the radiotrac-
ers (V)DMSA and MIBI. However, this was not demon-
strated in univariate or multivariate analysis for either tracer.
Cwikla and coworkers [27] reported a positive correlation
between MIBI uptake and malignant grade only for infiltrat-
ing ductal carcinomas (P=0.03). Recently, in 45 breast
cancer patients, we found that the difference in (V)DMSA
and MIBI uptake between lower and higher tumor grades
was not statistically different [21]. However, by calculating
the retention index ([delayed uptake – early uptake]
×100/early uptake), we found that lower grade tumors
had lower retention indices than did higher grade ones.
In our group of patients the majority of cancers were of
grade II or III. The lack of grade I cancers and the possible
individual subjective over- or underestimation of close con-
secutive grades (II and III) could offer an alternative expla-
nation for these observations.
The relationship between p53 expression and other prog-
nostic parameters is not yet clear. Contradictory findings
concerning tumor size and lymph node status have been
reported, but a strong relationship has been reported with
in situ carcinomas and their histologic types. Furthermore,
it has been demonstrated that p53 overexpression reflects
tumor aggressiveness and decreased disease free interval
following therapy. Our findings indicated no p53 depen-
dency of (V)DMSA or MIBI uptake in breast tumor in
simple and multivariate analyses.
C-erbB-2 over-expression has also been suggested to be a
prognostic factor in breast cancer. C-erbB-2 is found in
almost 60% of cases of high grade comedo-type DCIS
[33,34], in 10–40% of infiltrating ductal carcinomas, and in
only a few cases of infiltrating lobular carcinomas. C-erbB-2
expression has a close positive relationship with degree of
differentiation and number of infiltrated lymph nodes, and an
inverse correlation with the presence of hormonal receptors.
In contrast, in our series no significant correlation was found
in univariate and multivariate analyses between (V)DMSA or
MIBI uptake and c-erbB-2 expression.
Conclusion
In summary, the results of the present study suggest that
proliferative activity is a major independent factor affecting
(V)DMSA uptake in breast cancer. Tumor size was the
only independent parameter influencing MIBI uptake in
breast cancer. The negative correlation found between PR
and (V)DMSA uptake can be interpreted as indirect and
dependent on the negative correlation between Ki-67 and
Available online http://breast-cancer-research.com/content/6/2/R56
R61PR. The clinical significance of such an in vivo indicator of
cell proliferation activity could be useful for predicting the
prognosis and clinical behavior of an infiltrating breast
cancer, and in the detection of early preinvasive lesions.
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